Live cases: St George’s Hospital, London / St Francis, New York

An internationally recognized interventional cardiologist, Dr. Moses has performed more than 15,000 interventional procedures, authored over 600 publications, and served as lead investigator for numerous national and international clinical studies that have demonstrated the effectiveness and safety of coronary stent placement. In 2002, Dr. Moses was the lead investigator on a large clinical trial, the first in the U.S. that demonstrated the enormous benefit that led to FDA approval of the first drug-coated stent now used in the majority of interventional procedures in the U.S. Most recently in on the Executive Committee of PARTNER trial; they brought the first transcatheter aortic valve to clinical use in the U.S. He currently serves as Director of Interventional Cardiovascular Therapeutics at Columbia University Medical Center and as Director of Advanced Cardiac Interventions at St Francis Hospital and Heart Center in Roslyn, NY. He is also a pioneer in developing approaches involving minimally invasive surgery, angioplasty, gene therapy, novel imaging technologies and various support devices that allow for wider application of interventional cardiovascular procedures.

After training in Scotland, Interventional Cardiology Fellowship at CUMC, and Clinical Research Fellowship at Harvard University, she was a Consultant Interventional Cardiologist at the Golden Jubilee National Hospital and Associate Professor of Cardiology at the University of Glasgow, prior to moving back to New York in 2022.

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial.

Dr Simon Walsh has been working as a Consultant Cardiologist at the Belfast Trust for over 10 years. It is one of the largest NHS trusts in the UK. The centre performs ~2750 PCI per year, with 650-700 STEMI and calcium modification in ~10% of our PCI cases. Dr Walsh also works internationally as an educator, teaching advanced techniques for complex PCI and CTO PCI. This involves training visiting Cardiologists in Belfast retrograde CTO techniques, antegrade dissection and re-entry CTO techniques and other advanced PCI procedures. He has visited multiple centres in the UK, Ireland, Europe, Australia, Asia and North America to act as a visiting proctor for complex PCI and CTO PCI cases. Dr Walsh’s research interests include PCI, coronary artery disease, defibrillation, acute coronary syndromes and chronic total occlusions. Research responsibilities have included acting as a recruiting investigator for the >25 multicentre studies over the last 17 years. He acted as a primary investigator for numerous international trials including the Evolve, Noble, Leaders Free and Ischemia multicentre studies. He has been the lead UK investigator for the October trial, Syntax 2, Recharge and Ischaemia-CTO. He is also the Chief Investigator for the Consistent CTO, Celtic Bifurcation and Discrete CTO trials.